These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23330649)

  • 1. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK.
    Hall GC; McMahon AD; Dain MP; Wang E; Home PD
    Diabet Med; 2013 Jun; 30(6):681-6. PubMed ID: 23330649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
    Fu H; Curtis BH; Schuster DP; Festa A; Kendall DM
    Diabetes Technol Ther; 2014 Dec; 16(12):833-9. PubMed ID: 25068375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.
    Yu M; Mody R; Landó LF; Shui A; Kallenbach L; Slipski L; de Oliveira CP
    Clin Ther; 2017 Dec; 39(12):2399-2408. PubMed ID: 29196084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is insulin the preferred treatment for HbA1c >9%?
    Bloomgarden Z
    J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.
    Khunti K; Nikolajsen A; Thorsted BL; Andersen M; Davies MJ; Paul SK
    Diabetes Obes Metab; 2016 Apr; 18(4):401-9. PubMed ID: 26743666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
    Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
    Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
    Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
    J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
    Montvida O; Klein K; Kumar S; Khunti K; Paul SK
    Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world study of the concomitant use of biphasic insulin aspart 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes.
    Davies M; Alibegovic AC; Anil G; Braae UC; Jensen AB; Nordsborg RB
    Diabet Med; 2024 May; 41(5):e15267. PubMed ID: 38088483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world impact on monthly glucose-lowering medication cost, HbA
    Rose TN; Jacobs ML; Reid DJ; Bouwmeester CJ; Conley MP; Fatehi B; Matta TM; Barr JT
    J Am Pharm Assoc (2003); 2020; 60(1):31-38.e1. PubMed ID: 31611005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
    Lane W; Weinrib S; Rappaport J
    Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Curr Med Res Opin; 2018 Jun; 34(6):1125-1133. PubMed ID: 29557199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.